lung neoplasms/otok

Веза се чува у привремену меморију

Изаберите тип сортирања

Страна 1 од 16 резултати

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From Non-squamous NSCLC

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-squamous non-small cell lung cancer by assessing the treatment response, neurological symptoms and

Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

- Preeclampsia (PE) is a diverse multisystem syndrome defined as a new onset of hypertension along with evidence of significant multiorgan dysfunction in previously normotensive women 20 weeks of gestation (1) - The incidence of PE is around 2 - 8 % of pregnancies and it causes about 50,000 deaths

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally

Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib is safe, effective in the treatment of limited brain metastases with perilesional edema in non-small cell lung cancer. The sample size is 50. Patients start to take Anlotinib 1 week before the

Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Brain metastases (BM) develop in 22-54% of NSCLC patients during the disease course. NSCLC patients with BM with a median overall survival (OS) of 2-3 months when treated with systemic corticosteroid alone, and a median OS of 3-6 months when treated with whole brain radiation therapy (WBRT).

Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The investigators propose a longitudinal imaging pilot study composed of 20 Stage I-III NSCLC patients before, and six weeks after standard radiotherapy using a hybrid 3T-PET/MRI system (Biograph mMR, Siemens Healthcare) and a GE Revolution 256-slice CT scanner. The imaging protocol is designed to

Radiomics for Prediction of Survival in GBM

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Human oncologic tissues exhibit strong phenotypic differences. Due to advances in both acquisition and analysis methods of medical imaging technologies, the extraction of reliable and informative image features to quantify these differences is currently possible. Radiomics, the extraction of large

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

MK-3475 (MK-3475) is an IgG4 monoclonal antibody to PD1, which received a 'breakthrough therapy' designation for advanced melanoma from the FDA in January 2013. Preliminary results from the NSCLC cohort of a phase I dose expansion trial of MK-3475 were presented at the 2013 World Conference on Lung

Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Inclusion criteria: 1. Males and females ≥ 20 years of age 2. ECOG performance status of 0-1 3. Histologically or cytologically verified non-squamous NSCLC 4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with

HS-PCI in Locally Advanced Adenocarcinoma of the Lung

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Patients with locally advanced non-small cell lung cancer (LA-NSCLC) have an increased risk of developing central nervous system (CNS) metastases during the course of their disease. The brain is the most common site of failure after first-line therapies (independent of combined sequential or

PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Patients: 6 adults with type 2diabetes will be selected, ages between 25 and 50 years, with more than 5 and less than 10 years of disease, adherent to treatment with oral hypoglycemic agents or insulin, who agree to participate in the study through a written informed consent. Only those with a high

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

ABT-510: In the early 1990s, thrombospondin (TSP-1) was first recognized as an endogenously produced inhibitor of angiogenesis. Since then, thrombospondin has been shown to inhibit neovascularization and tumorigenesis in numerous mouse models. Its anti- angiogenesis properties have been localized to

Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Dose-limiting edema and effusions associated with cumulative docetaxel administraton have necessitated the recommendation that all patients should be premedicated with oral corticosteroids such as dexamethasone prior to docetaxel administration. Dexamethasone pre-medication may also decrease the

Претходна
1
2
Следећи

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима